ARIA phase I will test five-fraction MR-guided RT for early glottic cancer
The 20-patient ARIA study will test 5×8.5 Gy MR-guided adaptive RT with gating for cT1–2N0M0 glottic cancer.
Tag
trial
PSMA/MRI-guided prostate SABR with focal boost showed strong two-year imaging response
In ARGOS-CLIMBER, PSMA/MRI-guided five-fraction pelvic SABR produced a 67% PET complete response rate at two years with limited late GU toxicity.
HYPOCON tests biphasic chemoradiotherapy to target hypoxia in head and neck cancer
HYPOCON will test 40 Gy/20 fractions followed by 15 Gy/3 against 55 Gy/20, both with concurrent cisplatin.
Empty-bladder prostate SBRT met the EMPTY-RT acute safety endpoint
Empty-bladder SBRT was feasible in 85% of screened patients, with grade 2 or higher urinary toxicity of 28.1%.
Hypofractionated SIB reduced acute dermatitis in the randomized HYPOSIB trial
Grade 2 dermatitis fell from 38.6% to 25.3% with 16-fraction whole-breast radiotherapy plus simultaneous integrated boost.
4DCT ventilation accurately predicted lung function after cancer resection
4DCT ventilation predicted postoperative FEV1, FVC, and DLCO with concordance coefficients of 0.88–0.91 in the LIME trial.
Sleep adjustment avoided sedation in most pediatric radiotherapy fractions
A structured sleep protocol enabled sedation-free delivery in 96.4% of radiotherapy fractions among children younger than four years.
Stereotactic radiotherapy plus atezolizumab missed the AZTEC efficacy target
Neither fractionation schedule rejected the prespecified progression-free survival benchmark; durable benefit was confined to patients with oligometastatic disease.
Preoperative stereotactic radiotherapy shortened brain metastasis treatment without increasing early morbidity
Preoperative SRS/FSRT completed local therapy 22.5 days sooner than postoperative treatment, with similar 30-day morbidity; oncologic outcomes remain pending.
BARitOne will escalate oropharyngeal dose only for MRI-defined non-responders
BARitOne uses on-treatment diffusion MRI to increase gross tumour dose from 65 to 73 Gy only in predicted non-responders.
Early neuropsychological care did not improve three-month quality of life in brain metastases
ATHENA did not improve FACT-Br scores at three months, although an exploratory nine-month analysis favoured neuropsychological integration.
Durvalumab with radiotherapy achieved 39% two-year PFS in cCRT-ineligible NSCLC
Concurrent and consolidative durvalumab with definitive radiotherapy produced 39% two-year progression-free survival in patients ineligible for concurrent chemoradiotherapy.
Dose-escalated chemoradiotherapy improved nine-year survival in locally advanced rectal cancer
A 56 Gy simultaneous integrated boost improved nine-year survival and disease control compared with standard 50 Gy chemoradiotherapy.
SPPORT intensification did not worsen long-term quality of life
Short-term androgen deprivation impaired early sexual and hormonal quality of life, but treatment-arm differences were not clinically significant at five years.
FDG-PET-guided dose escalation did not improve control in advanced oropharyngeal and laryngopharyngeal cancers
Escalating metabolically active disease to 73.5 Gy did not improve locoregional control, disease-free survival, or overall survival versus 66 Gy.